hiv antibodies

Summary

Summary: Antibodies reactive with HIV ANTIGENS.

Top Publications

  1. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
  2. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
  3. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
  4. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
  5. ncbi Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
    Jinghe Huang
    HIV Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 491:406-12. 2012
  6. pmc Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 480:336-43. 2011
  7. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
  8. pmc Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 333:1633-7. 2011
  9. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
  10. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010

Detail Information

Publications252 found, 100 shown here

  1. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
    ..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
  2. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
    ....
  3. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
    ..In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk...
  4. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  5. ncbi Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
    Jinghe Huang
    HIV Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 491:406-12. 2012
    ..The highly conserved MPER is a target of potent, non-self-reactive neutralizing antibodies, suggesting that HIV-1 vaccines should aim to induce antibodies to this region of HIV-1 envelope glycoprotein...
  6. pmc Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 480:336-43. 2011
    ..In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand...
  7. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  8. pmc Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 333:1633-7. 2011
    Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests that vaccines that elicit such antibodies would be protective...
  9. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  10. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
    ..Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies...
  11. ncbi Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    Nature 393:648-59. 1998
    ..Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene...
  12. pmc A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield
    Robert Pejchal
    Department of Molecular Biology, Skaggs Institute for Chemical Biology and International AIDS Vaccine Initiative IAVI Neutralizing Antibody Center, nhe Scripps Research Institute, La Jolla, CA 92037, USA
    Science 334:1097-103. 2011
    ..Furthermore, our data suggest that the high neutralization potency of PGT 127 and 128 immunoglobulin Gs may be mediated by cross-linking Env trimers on the viral surface...
  13. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  14. pmc Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    Xueling Wu
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Science 333:1593-602. 2011
    ....
  15. pmc Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses
    Dennis R Burton
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 337:183-6. 2012
    ..Molecular characterizations of the antibodies and, most importantly, of the sites of vulnerability that they recognize give hope for the discovery of new vaccines and drugs...
  16. ncbi Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
    Peter D Kwong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 37:412-25. 2012
    ..The human immune system is capable of developing antibodies that broadly neutralize HIV-1--and an increasingly detailed view is accumulating for how effective immunity against HIV-1 can be generated...
  17. pmc Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Ming Li
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 79:10108-25. 2005
    ..These reference reagents will facilitate proficiency testing and other validation efforts aimed at improving assay performance across laboratories and can be used for standardized assessments of vaccine-elicited neutralizing antibodies...
  18. pmc Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
    Hua Xin Liao
    Duke University Human Vaccine Institute, Departments of Medicine and Immunology, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Nature 496:469-76. 2013
    ..These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination...
  19. pmc HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 492:118-22. 2012
    ..Thus, combinations of potent monoclonal antibodies can effectively control HIV-1 replication in humanized mice, and should be re-examined as a therapeutic modality in HIV-1-infected individuals...
  20. pmc Structural definition of a conserved neutralization epitope on HIV-1 gp120
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 445:732-7. 2007
    ..A site of vulnerability, related to a functional requirement for efficient association with CD4, can therefore be targeted by antibody to neutralize HIV-1...
  21. pmc Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996
    ..consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples...
  22. pmc Antibody-based protection against HIV infection by vectored immunoprophylaxis
    Alejandro B Balazs
    Division of Biology, California Institute of Technology, 1200 East California Boulevard, Pasadena, California 91125, USA
    Nature 481:81-4. 2012
    ..Our results suggest that successful translation of this approach to humans may produce effective prophylaxis against HIV...
  23. pmc Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 109:E3268-77. 2012
    Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-dependent epitopes on gp120...
  24. pmc Increasing the potency and breadth of an HIV antibody by using structure-based rational design
    Ron Diskin
    Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA
    Science 334:1289-93. 2011
    ..Together with the NIH45-46-gp120 structure, these results indicate that gp120 inner domain and bridging sheet residues should be included in immunogens to elicit CD4bs antibodies...
  25. pmc Structure of a V3-containing HIV-1 gp120 core
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Science 310:1025-8. 2005
    ..The extended nature and antibody accessibility of V3 explain its immunodominance. Together, the results provide a structural rationale for the role of V3 in HIV entry and neutralization...
  26. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  27. pmc Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
    Ann J Hessell
    Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA
    PLoS Pathog 5:e1000433. 2009
    ..The results raise the possibility that some epitopes on HIV may be better vaccine targets than others and support targeting the glycan shield of the envelope...
  28. ncbi Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 458:636-40. 2009
    ..Thus, the IgG memory B-cell compartment in the selected group of patients with broad serum neutralizing activity to HIV is comprised of multiple clonal responses with neutralizing activity directed against several epitopes on gp120...
  29. pmc Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    J R Mascola
    Division of Retrovirology, Walter Reed Army Institute of Research and Henry M Jackson Foundation, Rockville, Maryland 20850, USA
    J Virol 73:4009-18. 1999
    ..These data indicate a general correlation between in vitro neutralization and protection and suggest that a vaccine that elicits neutralizing antibody should have a protective effect against HIV-1 infection or disease...
  30. pmc Induction of immunity to human immunodeficiency virus type-1 by vaccination
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109, USA
    Immunity 33:542-54. 2010
    ....
  31. pmc Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 467:591-5. 2010
    ..Despite the low affinity of the polyreactive combining site, heteroligation demonstrably increases the apparent affinity of polyreactive antibodies to HIV...
  32. pmc Rapid evolution of the neutralizing antibody response to HIV type 1 infection
    Douglas D Richman
    Department of Pathology, Veterans Affairs San Diego Healthcare System and the University of California at San Diego, La Jolla, CA 92093 0679, USA
    Proc Natl Acad Sci U S A 100:4144-9. 2003
    ..These data argue that neutralizing antibody responses account for the extensive variation in the envelope gene that is observed in the early months after primary HIV infection...
  33. ncbi The role of antibodies in HIV vaccines
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Immunol 28:413-44. 2010
    ..Thus, current vaccine design efforts have focused on a more detailed understanding of these broadly neutralizing antibodies and their epitopes to inform the design of improved vaccines...
  34. pmc Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    D Noah Sather
    Seattle Biomedical Research Institute, Seattle, Washington 98109, USA
    J Virol 83:757-69. 2009
    ..Overall, our study indicates that more than one pathway leads to the development of broad cross-reactive neutralizing antibodies during HIV infection and that the virus continuously escapes their action...
  35. ncbi Antibody domain exchange is an immunological solution to carbohydrate cluster recognition
    Daniel A Calarese
    Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 300:2065-71. 2003
    ..The unique interdigitation of Fab domains within an antibody uncovers a previously unappreciated mechanism for high-affinity recognition of carbohydrate or other repeating epitopes on cell or microbial surfaces...
  36. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    ..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
  37. pmc Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
    Melissa D Simek
    International AIDS Vaccine Initiative, New York, NY 10028, USA
    J Virol 83:7337-48. 2009
    ..These elite neutralizers provide promising starting material for the isolation of broadly neutralizing monoclonal antibodies to assist in HIV-1 vaccine design...
  38. pmc The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection
    Elin S Gray
    National Institute for Communicable Diseases, Johannesburg, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 85:4828-40. 2011
    ....
  39. pmc The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120
    Rogier W Sanders
    Dept of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Virol 76:7293-305. 2002
    ....
  40. pmc Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    Iliyana Mikell
    Seattle BioMed, Seattle, Washington, USA
    PLoS Pathog 7:e1001251. 2011
    ....
  41. pmc HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes
    Tommy Tong
    Torrey Pines Institute for Molecular Studies, San Diego, California, USA
    J Virol 86:3574-87. 2012
    ..This suggests that trimer VLPs bear essentially pure native trimer that should allow its unfettered evaluation in a vaccine setting...
  42. pmc The development of CD4 binding site antibodies during HIV-1 infection
    Rebecca M Lynch
    Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA
    J Virol 86:7588-95. 2012
    ....
  43. pmc Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012
    ..No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials...
  44. pmc Elicitation of structure-specific antibodies by epitope scaffolds
    Gilad Ofek
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:17880-7. 2010
    ..Epitope scaffolds thus provide a means to elicit antibodies that recognize a predetermined target shape and sequence, even if that shape is transient in nature, and a means by which to dissect factors influencing such elicitation...
  45. pmc Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
    P Roben
    Department of Immunology, Scripps Research Institute, La Jolla, California 92037
    J Virol 68:4821-8. 1994
    ..Apparently, subtle differences in the gp120 epitope recognized allow some members of the group of anti-CD4bs antibodies to bind to the functionally relevant envelope glycoprotein complex and to neutralize virus more efficiently...
  46. pmc Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    Yuxing Li
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892 3005, USA
    J Virol 83:1045-59. 2009
    ..These data allow a more detailed understanding of the humoral responses to the HIV-1 Env protein and provide insights regarding the most relevant targets for HIV-1 vaccine design...
  47. pmc Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1
    Marie Pancera
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3027, USA
    J Virol 84:8098-110. 2010
    ..The structural and functional details of extraordinary CDR H3 and extensive affinity maturation provide insights into the neutralization mechanism of and the elicitation pathway for broadly neutralizing antibodies like PG9 and PG16...
  48. pmc Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    J Exp Med 209:1469-79. 2012
    ..Therefore, vaccines aimed at eliciting anti-HIV-1 serologic breadth and potency should not be limited to single epitopes...
  49. pmc Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Cell 153:126-38. 2013
    ..Thus, in bNAbs, FWRs play an essential role beyond scaffolding the CDR loops and their unusual contribution to potency and breadth should be considered in HIV-1 vaccine design...
  50. pmc The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120
    Christopher N Scanlan
    The Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom
    J Virol 76:7306-21. 2002
    ....
  51. pmc Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
    P W Parren
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:8340-7. 2001
    ..The significance of such substerilizing neutralizing antibody titers in the context of a potent cellular immune response is an important area for further study...
  52. pmc Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
    ..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies...
  53. ncbi Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  54. ncbi Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence
    Bharat S Parekh
    Division of AIDS, STD, TB Laboratory Research, and Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS Res Hum Retroviruses 18:295-307. 2002
    ..This assay should be useful for detecting recent HIV-1 infection and for estimating incidence among diverse HIV-1 subtypes worldwide...
  55. pmc A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 6:e1001028. 2010
    ..In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera...
  56. pmc Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals
    Susan Moir
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 205:1797-805. 2008
    ..These data suggest that HIV-associated premature exhaustion of B cells may contribute to poor antibody responses against HIV in infected individuals...
  57. ncbi HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
    Peter D Kwong
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 420:678-82. 2002
    ..Because this solution is available for cell-surface receptors but not for most antibodies, conformational masking enables HIV-1 to maintain receptor binding and simultaneously to resist neutralization...
  58. pmc Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function
    Javier Guenaga
    IAVI Neutralizing Antibody Center at The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 8:e1002806. 2012
    ..The data suggest a new mechanism of action, important for vaccine design, in which the 2F5 CDRH3 contacts and destabilizes the MPER helix downstream of its core epitope to allow induction of the extended-loop conformation...
  59. pmc Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
    Lei Chen
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 326:1123-7. 2009
    ..This incompatibility, the consequence of slight differences in CD4BS recognition, renders HIV-1 resistant to all but the most accurately targeted antibodies...
  60. pmc HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes
    Nicole A Doria-Rose
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:3393-7. 2012
    ..Predicted neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel...
  61. pmc Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies
    Zhongyu Zhu
    National Cancer Institute, Frederick, Maryland 21702 1201, USA
    J Virol 85:11401-8. 2011
    ....
  62. pmc Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
    Nicole A Doria-Rose
    LIR, NIAID, National Institutes of Health, Bldg 10, Rm 7N246, 10 Center Dr, Bethesda, MD 20892, USA
    J Virol 83:188-99. 2009
    ..These data describe the breadth and titer of serum NAb and the frequency and phenotype of HIV-specific B cells in a cohort of patients with broad cross-neutralizing antibody responses that are potential goals for vaccines for HIV...
  63. pmc Rational antibody-based HIV-1 vaccine design: current approaches and future directions
    Laura M Walker
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    Curr Opin Immunol 22:358-66. 2010
    ....
  64. pmc Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion
    Trudy Dobbs
    HIV Immunology and Diagnostics Branch, Mailstop D12, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA
    J Clin Microbiol 42:2623-8. 2004
    ..This information provides baseline data for the successful transfer of BED-CEIA to other laboratories and the use of BED-CEIA for the detection of recent HIV seroconversion and the calculation of incidence estimates worldwide...
  65. ncbi Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design
    E O Saphire
    Department of Molecular Biology, Department of Immunology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 293:1155-9. 2001
    ..The structure, together with mutagenesis studies, provides a rationale for the extensive cross-reactivity of b12 and a valuable framework for the design of HIV-1 vaccines capable of eliciting b12-like activity...
  66. ncbi Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold
    Mihai L Azoitei
    Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
    Science 334:373-6. 2011
    ..The method can be generalized to design other functional proteins through backbone grafting...
  67. ncbi A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120
    Simon Beddows
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Room W 805, New York, NY 10021, USA
    Virology 360:329-40. 2007
    ..When antibodies able to neutralize HIV-1(JR-FL) were detected, antigen depletion studies showed they were not directed at the V3 region but were targeted at other, undefined gp120 and also non-gp120 epitopes...
  68. pmc Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120
    Anthony P West
    Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA
    Proc Natl Acad Sci U S A 109:E2083-90. 2012
    ..Our results bear on vaccine development and structure-based design to improve the potency and breadth of anti-CD4bs antibodies...
  69. ncbi Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges
    Morgane Bomsel
    Mucosal Entry of HIV 1 and Mucosal Immunity, Cell Biology and Host Pathogen Interactions Department, Cochin Institute, CNRS UMR 8104, 22 rue Mechain, Paris, France
    Immunity 34:269-80. 2011
    ..The protection observed challenges the paradigm whereby circulating antiviral antibodies are required for protection against HIV-1 infection and may serve in designing a human vaccine against HIV-1-AIDS...
  70. pmc Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 317:1930-4. 2007
    ....
  71. pmc Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    J Exp Med 208:2237-49. 2011
    ..These data suggest that the majority of gp41-binding antibodies produced after acute HIV-1 infection are cross-reactive responses generated by stimulating memory B cells that have previously been activated by non-HIV-1 antigens...
  72. pmc Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection
    Evelien M Bunnik
    Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory and Center for Infection and Immunity Amsterdam, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Virol 82:7932-41. 2008
    ....
  73. pmc Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC
    Tara G Edmonds
    Department of Molecular and Cellular Pathology, University of Alabama at Birmingham, 701 19th Street South, Birmingham, AL 35294, USA
    Virology 408:1-13. 2010
    ..In PBMC, NAb activity can be analyzed either within a single or multiple cycles of replication. These results represent advancement toward a standardizable PBMC-based neutralization assay for assessing HIV-1 vaccine immunogen efficacy...
  74. pmc Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways
    Rong Rong
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
    PLoS Pathog 5:e1000594. 2009
    ....
  75. pmc Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
    Gilad Ofek
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Instiutes of Health, Bethesda, MD 20892, USA
    J Virol 78:10724-37. 2004
    ..Based on these structural and biochemical results, immunization strategies for eliciting 2F5- and 4E10-like broadly neutralizing anti-HIV-1 antibodies are proposed...
  76. pmc Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions
    Victor Buzon
    Unit of Virus Host Cell Interactions UMI 3265, Université Joseph Fourier EMBL CNRS, Grenoble, France
    PLoS Pathog 6:e1000880. 2010
    ....
  77. pmc Enhanced HIV-1 neutralization by antibody heteroligation
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 109:875-80. 2012
    ..Heterotypic bivalent binding enhanced neutralization compared with the parental antibodies. We conclude that antibody recognition and viral neutralization of HIV can be improved by heteroligation...
  78. ncbi Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes
    Bharat S Parekh
    Division of Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS Res Hum Retroviruses 27:265-73. 2011
    ..The determination of ω with more data and new methodology suggests that ω of the BED-CEIA varies between different subtypes and/or populations. These estimates for ω may affect incidence estimates in various studies...
  79. pmc Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals
    Georgia D Tomaras
    Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Box 2926, Durham, NC 27710, USA
    J Virol 85:11502-19. 2011
    ..The broadly reactive HIV-1 neutralization observed in some subjects is mediated by antibodies targeting several conserved regions on the HIV-1 envelope glycoprotein...
  80. pmc Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins
    Craig B Wilen
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Virol 85:8514-27. 2011
    ..These data suggest that there are subtle but significant structural differences between T/F and chronic clade B Envs that may have implications for HIV-1 transmission and the design of effective vaccines...
  81. pmc High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection
    Christy L Lavine
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 86:2153-64. 2012
    ....
  82. pmc An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV
    Jennifer D Watkins
    Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 6:e18207. 2011
    ....
  83. pmc Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization
    Mikyung Kim
    Laboratory of Immunobiology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Nat Struct Mol Biol 18:1235-43. 2011
    ..Hence, target neutralization through this lipid-embedded viral segment places stringent requirements on the plasticity of the antibody combining site...
  84. pmc Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors
    Elin S Gray
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 83:8925-37. 2009
    ....
  85. ncbi Measuring HIV neutralization in a luciferase reporter gene assay
    David C Montefiori
    Department of Surgery, Laboratory for AIDS, Vaccine Research and Development, Duke University Medical Center Durham, NC, USA
    Methods Mol Biol 485:395-405. 2009
    ..This assay has become the main endpoint neutralization assay used by the NIH-sponsored HIV Vaccine Trials Network and by a growing number of laboratories worldwide...
  86. ncbi Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission
    Cynthia A Derdeyn
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294 USA
    Science 303:2019-22. 2004
    ..This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design...
  87. ncbi Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection
    Angelo De Milito
    Microbiology and Tumor Biology Center, Karolinska Institute, and Gay Men s Health Clinic, The Soder Hospital, Stockholm, Sweden
    Blood 103:2180-6. 2004
    ..Our results may be relevant to the design of HIV-1 therapeutical vaccines and to the clinical management of HIV-1-infected patients...
  88. pmc B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study
    Barton F Haynes
    Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
    Nat Biotechnol 30:423-33. 2012
    ..This approach, which should be applicable to many infectious agents, holds promise for the construction of vaccines that can drive B cells along rare but desirable maturation pathways...
  89. pmc The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection
    John B Lynch
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Virol 85:5252-61. 2011
    ....
  90. pmc Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins
    George Sellhorn
    Seattle BioMed, Seattle, Washington, USA
    J Virol 86:128-42. 2012
    ..The heterotrimeric gp140s elicited broader anti-tier 1 isolate neutralizing antibody responses than did the homotrimeric gp140s...
  91. ncbi The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus
    Gunilla B Karlsson Hedestam
    Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
    Nat Rev Microbiol 6:143-55. 2008
    ..Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens...
  92. pmc Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity
    Manish Sagar
    Department of Medicine, Brigham and Women s Hospital, Cambridge, Massachusetts 02139, USA
    J Virol 80:9586-98. 2006
    ..These studies suggest that changes within the V1-V2 envelope domains over the course of an infection influence sensitivity to autologous neutralizing antibodies and may also impact host receptor/coreceptor interactions...
  93. pmc Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions
    Erin M Scherer
    Department of Immunology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 107:1529-34. 2010
    ....
  94. pmc A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120
    Emma T Crooks
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, USA
    Virology 366:245-62. 2007
    ..Therefore, to make progress toward a more effective VLP-based vaccine, we will need to find ways to refocus the attention of B cells on native trimers...
  95. pmc Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization
    Curtis P Bradney
    Department of Medicine, Human Vaccine Institute, Center for AIDS Research, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 76:517-24. 2002
    ..These results indicate that the proinflammatory cytokines IL-1alpha, IL-12, and IL-18 can replace CT as a mucosal adjuvant for antibody induction and are important candidates for use as mucosal adjuvants with HIV and other vaccines...
  96. pmc Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16
    Katie J Doores
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 84:10510-21. 2010
    ..This information may be valuable for the design of immunogens to elicit PG9 and PG16-like antibodies, as well as constructs for cocrystallization studies...
  97. pmc Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection
    Penny L Moore
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
    PLoS Pathog 5:e1000598. 2009
    ..While the mechanism of neutralization escape appears to vary between individuals, the involvement of limited regions suggests there might be common vulnerabilities in the HIV-1 subtype C transmitted envelope...
  98. pmc The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection
    Penny L Moore
    National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 82:1860-9. 2008
    ..These data suggest that the C3 and V4 regions combine to form important structural motifs and that epitopes in this region are major targets of the early autologous neutralizing response in HIV-1 subtype C infection...
  99. pmc Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile
    Richard Strasser
    Department of Applied Genetics and Cell Biology, University of Natural Resources and Applied Life Sciences, 1190 Vienna, Austria
    J Biol Chem 284:20479-85. 2009
    ....
  100. pmc A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies
    Gary Frey
    Laboratory of Molecular Medicine, Children s Hospital, and Department of Pediatrics, Harvard Medical School, 320 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:3739-44. 2008
    ..These results help explain the rarity of 2F5- and 4E10-like antibody responses and suggest a strategy for eliciting them...
  101. ncbi Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140
    Suganya Selvarajah
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    AIDS Res Hum Retroviruses 24:301-14. 2008
    ..However, the results also show that in order to elicit broadly neutralizing antibodies that target conserved epitopes, the soluble gp140 trimer immunogen template will require further modifications...

Research Grants63

  1. Targeting the oral cavity epithelium for inducing mucosal immunity against HIV
    Harvinder Singh Gill; Fiscal Year: 2012
    ..intramuscular (IM) routes of immunization in rabbits using well characterized HIV antigens with focus on anti-HIV antibodies in the saliva, and at other distal mucosa...
  2. Protective Human Monoclonal Antibodies to HIV-1
    SUSAN B ZOLLA-PAZNER; Fiscal Year: 2012
    Attempts to induce broadly reactive and potent protective anti-HIV antibodies (Abs) by immunization of humans have been unsuccessful...
  3. Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies
    JEFFREY VICTOR RAVETCH; Fiscal Year: 2013
    ..Our project goals are to discover the mechanisms by which anti-HIV antibodies can prevent or treat infection (through Fab-mediated neutralization and Fc-mediated effector functions) and ..
  4. Improving blood safety and HIV testing in Brazil: a randomized controlled trial
    THELMA THEREZINHA GONCALEZ; Fiscal Year: 2013
    ..Although all donated blood is screened for HIV antibodies, a residual risk of contamination persists due to the immunological window period before antibodies are ..
  5. National Resource for Mass Spectrom of Biological Macromolecules
    Brian T Chait; Fiscal Year: 2013
    ..Our DBPs will seek to (1) gain an understanding of broadly neutralizing anti-HIV antibodies;(2) develop improved methods for elucidating the structures of conotoxins as potential therapeutics;(3) ..
  6. PRIMARY HIV PREVENTION IN PREGNANT AND LACTATING UGANDAN WOMEN:A RANDOMIZED TRIAL
    Jaco Homsy; Fiscal Year: 2013
    ..majority of the millions of pregnant women who are tested and counseled for HIV every year test negative for HIV antibodies. Keeping these women uninfected is a critical component of the World Health Organization (WHO) global strategy ..
  7. HIV vaccine development using humanized mice
    ROBERT THOMAS WOODLAND; Fiscal Year: 2013
    ..these monoclonals frequently demonstrated polyreactivity or self reactivity which may be a key feature of anti-HIV antibodies with broadly neutralizing potential...
  8. Intersubtype recombinants for polyvalent anti-HIV vaccine
    Yong Gao; Fiscal Year: 2013
    ..models immunized with heterogeneous envA/D recombinants-based vaccine and screen for broadly neutralizing anti-HIV antibodies. In Aim 3, we will test humoral and cellular responses in Rhesus Macaques, and find out the breadth and ..
  9. Trapping HIV in mucus with IgG antibodies
    SAMUEL LAI; Fiscal Year: 2012
    ..Recent evidence suggests anti- HIV antibodies protect against mucosal HIV challenges in animals and humans, yet the mechanisms of protection remain poorly ..
  10. Point-of-Care HIV Antigen/Antibody Diagnostic Device
    Michael J Lochhead; Fiscal Year: 2011
    ..individuals remain the most difficult to identify, as infectivity is highest prior to the appearance of the HIV antibodies that serve as the basis for serological diagnostics...
  11. GBV-C E2 protein mimics a cellular antigen involved in HIV-1 entry
    Jinhua Xiang; Fiscal Year: 2013
    ..Administration of a cocktail of these broadly neutralizing HIV antibodies decreased HIV viral load in infected humans and to reduced HIV transmission in a monkey model of HIV ..
  12. Characterization of Antibody-Dependent Cellular Cytotoxicity in HIV Infection
    ADJOA R SMALLS-MANTEY; Fiscal Year: 2013
    ..abstract_text> ..
  13. Point Detection of Pathogens in Oral Samples via UPT
    Daniel Malamud; Fiscal Year: 2010
    ..will continue development of an HIV point-of-care device that monitors viral antigen, nucleic acid, and anti-HIV antibodies. Our bacterial studies will be extended to S...
  14. Penile transmission and neutralization of pathogenic SIVsmm
    George M Shaw; Fiscal Year: 2013
    ..transmissibility of SIV/HIV during the acute infection period, and the relative protective effect of anti-SIV/HIV antibodies in chronic infection on forward transmission...
  15. Testing of novel system to deliver VRC01 in mouse model
    Hans Peter Kiem; Fiscal Year: 2012
    ..proof-of-concept studies have demonstrated the ability to induce secretion of broadly neutralizing anti-HIV antibodies from autologous human cell with a lentiviral vector...
  16. Stapled Antigens for HIV-1 Vaccination
    LOREN DAVID WALENSKY; Fiscal Year: 2012
    ..Several naturally-occurring anti-HIV antibodies specifically recognize structured amino acid sequences of gp41, a dynamic fusion protein that adopts a ..
  17. Knock-in mice expressing germline-reverted broadly neutralizing HIV antibodies
    David Nemazee; Fiscal Year: 2013
    ..These knock-in gl-bNAb mice will be ideal for working out the best ligands and methods for testing in human immunization. ..
  18. Point-of-Care HIV Antigen/Antibody Diagnostic Device
    Michael J Lochhead; Fiscal Year: 2013
    ..individuals remain the most difficult to identify, as infectivity is highest prior to the appearance of the HIV antibodies that serve as the basis for serological diagnostics...
  19. HIV Envelope gp120-induced immunosuppression
    Catarina E Hioe; Fiscal Year: 2011
    ..HIV gp120 is an important target for anti-HIV antibodies. Since it has become clearer that induction of antibody responses is an indispensable element for HIV vaccines,..
  20. Multifunctional Human Anti-HIV Antibodies
    Carlos F Barbas; Fiscal Year: 2013
    ..This multi-specific immunotherapeutic would provide potent long-lived anti-HIV therapy/prophylaxis and would be very hard for HIV-1 to evolve resistance against. ..
  21. Probing the germlines of broadly neutralizing anti-HIV antibodies in knockin mice
    Dennis R Burton; Fiscal Year: 2012
    ..To understand how to better induce broadly neutralizing HIV antibodies it is important to identify the appropriate B cell precursors and to stimulate them with effective antigens...
  22. THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HIV TRANSMISSION
    Julie M Overbaugh; Fiscal Year: 2013
    ..However, variable results across studies of maternal and infant HIV antibodies in relation to transmission has hindered our ability to gain a clear picture f immune correlates in MTCT...
  23. Impact of Drug Policy Reform on the HIV Risk Environment among IDUs in Tijuana
    Steffanie A Strathdee; Fiscal Year: 2010
    ..recruit a cohort of 750 IDUs in Tijuana who will undergo semi-annual quantitative interviews and testing for HIV antibodies. At each visit, a sub- sample who report receiving a 1st, 2nd or 3rd strike for drug possession will undergo ..
  24. Boosting anti-HIV immunity through manipulation of Tfh function.
    Elias K Haddad; Fiscal Year: 2013
    ..memory B cell compartment with these cells dying prematurely and producing significantly lower levels of anti-HIV antibodies when compared to natural controllers...
  25. Structural Basis of Antibody-Mediated Neutralization of HIV
    Pamela J Bjorkman; Fiscal Year: 2012
    ..We will systematically analyze new anti-HIV antibodies with goals of understanding their protective mechanisms and improving antibodies for passive delivery ..
  26. Immunoglobulin CDR-H3 and neutralizing antibodies to HIV
    Harry Schroeder; Fiscal Year: 2009
    ..To test the role of long, hydrophobic CDR-H3s in permitting the generation of broadly neutralizing anti-HIV antibodies, Dr...
  27. NKT cells as modulators of AIDS vaccine efficacy
    Amitinder Kaur; Fiscal Year: 2013
    ..immunity, elicit an effective cytolytic and polyfunctional HIV-specific T cell response along with anti-HIV antibodies that have broadly directed neutralization activity and antibody dependent cellular cytotoxicity (ADCC) ..
  28. Molecular basis of ADCC-mediated HIV protection
    Eric J Sundberg; Fiscal Year: 2013
    ..to Fc?RIIIa throughout the early stages of HIV infection;and (iii) that a panel of broadly neutralizing HIV antibodies exhibits widely varying affinities to Fc?RIIIa...
  29. Accumulation of VH replacement products in HIV patients
    Zhixin Zhang; Fiscal Year: 2012
    ..Understanding the underlying mechanisms will allow us to regulate VH replacement and facilitate the generation of effective anti-HIV antibodies in future vaccine design.
  30. Efficacy Testing of HIV-Specific Microbicides in Humanized Mice
    Ramesh Akkina; Fiscal Year: 2012
    ..compounds with novel mechanisms of action and identification of potent broadly neutralizing anti-HIV antibodies (bNAb) provides us with a unique opportunity to test new approaches for prevention of HIV sexual transmission...
  31. A new approach to quantitative, point-of-care serology
    Kevin W Plaxco; Fiscal Year: 2013
    ..We have recently demonstrated a reagentless, electrochemical method, termed E-DNA sensors that can detect anti-HIV antibodies in undiluted human serum at levels thousands of times lower than those seen in HIV-positive patient samples...
  32. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis R Burton; Fiscal Year: 2013
    ..protection against mucosal HIV challenge and (3) To investigate in vitro how monoclonal and polyclonal anti-HIV antibodies mediate the extra-neutralizing activities shown in Aims 1 and 2 to be crucial in antibody protection...
  33. HUMAN IMMUNODEFICIENCY VIRUS AND HEMATOPOIESIS
    Colin Sieff; Fiscal Year: 1993
    ..Infection of hematopoietic progenitor cells, suppression induced by HIV antibodies or other proteins, or a combination of these insults...
  34. HIGH RISK COHORTS IN KENYA; PROSTITUTES AND TRUCKDRIVERS
    Joan Kreiss; Fiscal Year: 1993
    ..truck drivers employed by two large trucking companies in Mombasa will be screened for the presence of HIV antibodies and invited to participate in a prospective cohort study if HIV seronegative...
  35. Molecular epidemiology/HIV/STD patients/IVDUs/India
    Ramesh Paranjape; Fiscal Year: 2009
    ..Patients attending STD and IVDU clinics will be screened for HIV antibodies. Those positive for antibody will undergo detuned EIA for identifying recent HIV infections...
  36. Assessing HIV in Hidden Populations: A Feasibility Study
    Patricia Case; Fiscal Year: 2006
    ..The specific aims of this project are: 1) To test the reliability of semen and HIV antibodies in discarded or collected condoms in the laboratory and assess fitness of collected specimens for HIV testing ..
  37. Engineering Stable, Soluble, and Trimeric HIV gp140 by Paired Cys Scanning
    BENJAMIN JACOB DORANZ; Fiscal Year: 2013
    ..Many of the most potently neutralizing HIV antibodies identified to date preferentially bind the trimeric structure of Env...
  38. NEW ASSAYS FOR DIRECT DETECTION OF VIRAL NUCLEIC ACIDS
    Larry Mimms; Fiscal Year: 2000
    ..Currently, the enzyme immunoassays employed by blood banks for the detection of HIV antibodies are required to detect the presence of HIV-1 and HIV-2 antibodies; these tests have been shown to detect many ..
  39. ORAL SECRETORY IMMUNITY TO HUMAN IMMUNODEFICIENCY VIRUS
    DAVID ARCHIBALD; Fiscal Year: 1990
    ....
  40. Characterization of Novel Polyreactive Anit-HIV Anitbodies Autoimmunity
    Maureen Goodenow; Fiscal Year: 2009
    ..by applicant): An effective HIV vaccine should induce in a diverse human population broadly-neutralizing anti-HIV antibodies [bnHIV-Ab] that target most or all HIV subtypes...
  41. COXSACKIEVIRUSES AS CHIMERIC HIV VACCINE VECTORS
    Steven Tracy; Fiscal Year: 2001
    ..of a successful anti-HIV vaccine formulation should be the ability to provide active, protective anti-HIV antibodies (including mucosal) and CMI responses...
  42. HETEROSEXUAL HIV TRANSMISSION
    Kenneth Mayer; Fiscal Year: 1991
    ..Four thousand five hundred persons will be screened for HIV antibodies over 2-3 years and about 1/4 will be enrolled utilizing an algorithm to detect individuals at high risk for ..
  43. IN VIVO ACTIVITY OF ANTIGP41 IMMUNOTOXINS
    Seth Pincus; Fiscal Year: 1999
    ..Degylcosylated ricin A-chain (dRAC) has been coupled to monoclonal anti-HIV antibodies to construct ITs that kill HIV-infected cells...
  44. MUCOSAL PLANTIBODIES: ANTI-HIV
    Kevin Whaley; Fiscal Year: 2002
    ..These HIV antibodies can be combined with antibodies against other sexually transmitted disease pathogens already being produced in ..
  45. IMMUNOSENSOR FOR HIV ANTIBODIES
    JAMES ZULL; Fiscal Year: 1992
    ..When a responding sensor is developed, we will examine the response to the HIV antibodies present in blood of individuals with AIDS...
  46. CATALYTIC HIV ANTIBODIES
    Sudhir Paul; Fiscal Year: 2002
    ..In addition, the covalently reactive gp120 analogs have the potential to serve as prototypes for vaccines that can elicit catalytic immunity for the purpose of prophylaxis against HIV-1. ..
  47. HIV INFECTION OF HUMAN PLACENTAL CELLS
    Kathleen McGann; Fiscal Year: 1993
    ..We will characterize the viral entry pathway in placental cells and examine the effect of anti-HIV antibodies in neutralizing or possibly enhancing placental infection...
  48. Rapamycin Enhanced Efficiency of Anti-HIV Antibodies
    Antony Dimitrov; Fiscal Year: 2007
    ..The objective of this Phase I SBIR proposal is to identify potential combinations of rapamycin and antiviral antibodies that may have clinical potential. [unreadable] [unreadable] [unreadable]..
  49. REDUCING HIV & DOMESTIC VIOLENCE RISK IN WOMEN OFFENDERS
    Michael Stark; Fiscal Year: 2004
    ..Testing for HIV antibodies will occur at baseline and at month 10...
  50. DAYTON-COLUMBUS AIDS OUTREACH/PREVENTION PROGRAM
    Harvey Siegal; Fiscal Year: 1991
    ..s, and county jails as contact sites. These objects will provide data about risk behaviors and be tested for HIV antibodies. Seropositives, using standard health department protocols, will be referred for those AIDS counseling and ..
  51. FIBEROPTIC SENSOR FOR HIV ANTIBODIES
    Edward Carome; Fiscal Year: 1991
    ..This peptide has one cysteine for crosslinking, and has been found to bind HIV antibodies in all infected individuals examined, while showing no binding to multiple control sera...
  52. DEVELOPING RNA MIMOTOPES OF HIV ANTIGENS
    Bruce Sullenger; Fiscal Year: 1999
    ..HIV target-peptide epitopes for binding to these antibodies; and (3) To immunize animals with these RNA mimotopes and determine if such immunization results in the generation of anti-RNA and anti-HIV antibodies in the vaccinated animals.
  53. The CD4 Binding Site on HIV gp120 as a Vaccine Antigen
    Martin Teintze; Fiscal Year: 2003
    ..of a plant virus that can be expressed and assembled in yeast, and determine which constructs can bind anti-HIV antibodies; 3) synthesize the peptide sequences and determine their three-dimensional structures when bound to the ..
  54. BEHAVIOR CHANGE IN YOUNG ADULTS AT RISK FOR AIDS
    Arlene Stiffman; Fiscal Year: 1991
    ..During each reinterview period, the blood samples would be tested for HIV antibodies and other factors that might increase the youth's risk, such as syphilis and Hepatitis B.
  55. Novel Biological Activities of Anti-Viral Antibody
    Donald Forthal; Fiscal Year: 2006
    ..This project may provide crucial insights for guiding the development of vaccines, immunoprophylaxis and immunotherapy. ..
  56. AIDS CLINICAL STUDIES GROUP
    Michael Grieco; Fiscal Year: 1993
    ..Studies on the Specificity and Regulation of Anti-HIV Antibodies Using Human Monoclonal Antibody Technology...
  57. NCRR FACSAria Cell Sorter
    Barton Haynes; Fiscal Year: 2004
    ..Advisory committees, institutional support, financial support for continued maintenance, and management plans are in place to insure that the instrument will be fully and appropriately utilized. ..
  58. DESIGN OF NOVEL IMMUNOGENS AND ADJUVANTS FOR HIV VACCINE
    Barton Haynes; Fiscal Year: 2003
    ..abstract_text> ..
  59. PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION
    Jiri Mestecky; Fiscal Year: 2006
    ..Results of these studies will generate information concerning previously unexplored inflammatory pathways that participate in the development of PD. ..
  60. Familial IgA Nephropathy: Genetic and Metabolic Studies
    Jiri Mestecky; Fiscal Year: 2006
    ..abstract_text> ..
  61. NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES
    Dennis Burton; Fiscal Year: 2004
    ..To examine the impact of passive immunization in immunoprophylaxis and immunotherapy of a smallpox-like disease in a non-human primate model, we will use an experimental model of monkeypox virus infection ..
  62. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2007
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. [unreadable] [unreadable] [unreadable]..